Proactive Investors - Run By Investors For Investors

VolitionRx well positioned as it enters Q2 after strengthening balance sheet

Cameron Reynolds, chief executive of VolitionRx Limited (NYSE AMERICAN:VNRX), tells Proactive London's Andrew Scott they're in a good place after again strengthening the balance sheet in recent weeks with a further $5 million in warrants exercised for cash.

''Total cash in hand that gives us around $21.2mln ... so it's a really good runway to get our milestones completed''.

Reynolds also updates on operational developments including their first large-scale lung cancer study being carried out in Taiwan.

 
View full VNRX profile View Profile

VolitionRx Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use